Louisiana: A federal appeals court in the United States has issued a ruling that significantly limits access to the abortion pill Mifepristone, reinstating requirements for in-person dispensing and curbing telemedicine distribution.
The decision, delivered by the US Fifth Circuit Court of Appeals, temporarily blocks a 2023 regulation by the Food and Drug Administration that allowed healthcare providers to prescribe and mail abortion pills without requiring an in-person consultation.
Ruling tightens access in restrictive states
The move is expected to particularly impact states where abortion is banned or heavily restricted, limiting access to medication abortion, currently the most common method of terminating pregnancies in the US.
The ruling stems from a lawsuit led by the state of Louisiana, which argued that expanded access to abortion pills undermines its laws recognising fetal rights from conception.
In its order, the court stated that the FDA’s policy conflicted with Louisiana’s legal stance that unborn children are entitled to legal protection.
Legal battle follows earlier Supreme Court decision
The latest decision comes after the US Supreme Court in 2024 unanimously rejected an earlier challenge seeking to restrict access to mifepristone. However, that ruling left room for future legal challenges, paving the way for the current case.
The appellate ruling also overrides a recent lower court decision that had paused proceedings while a federal review of the drug’s regulation was underway.
Sharp divide among officials
Louisiana Attorney General Liz Murrill welcomed the decision, stating that previous rules had enabled widespread use of abortion medication in violation of state law. In contrast, Julia Kaye of the American Civil Liberties Union criticised the ruling, arguing that it contradicts established scientific evidence and legal precedent.
Meanwhile, New York Attorney General Letitia James affirmed that abortion access, including medication abortion, will remain protected in New York.
How the abortion pill works
Mifepristone is part of a two-drug regimen commonly used for early pregnancy termination. It works by blocking progesterone, a hormone necessary to sustain pregnancy. A second drug, misoprostol, is then used to induce uterine contractions and complete the process.
Approved in the US in 2000, mifepristone’s use was expanded in 2016 to include pregnancies up to 10 weeks. During the COVID-19 pandemic, the FDA temporarily lifted in-person dispensing requirements, later making the change permanent in 2023.
Safety and usage data
According to medical authorities, including the American College of Obstetricians and Gynaecologists, the combination of mifepristone and misoprostol is considered safe and effective.
Studies indicate the regimen is approximately 95 percent effective in terminating early pregnancies, with fewer than 1 percent of cases requiring additional medical intervention. More than 3.7 million women in the US used Mifepristone between 2000 and 2018, based on FDA data.
Ongoing legal uncertainty
The case highlights the continuing legal and political battles surrounding abortion access in the US following the rollback of nationwide protections. As litigation continues, access to medication abortion remains subject to shifting court decisions and state-level regulations.
POPULAR | Beyond the Collars: International Workers’ Day redefines respect
